News
Media
Conferences
Publication
Job Board
CME/CE
Partners
Editorial
Resources
Subscribe

Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

|Slideshows|August 20, 2020

10 Measures and Outcomes to Assess Progress in Eradicating Racism

Author(s)H. Steven Moffic, MD, Rahn K. Bailey, MD, Frank A. Clark, MD

Suggestions to assess outcomes and measure success levels in combatting racism.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Latest CME

Southern California Psychiatry Conference

In-Person Event

Southern California Psychiatry Conference

July 10-11, 2026

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Trending on Psychiatric Times

Developing Next-Generation Psychedelic Treatments: Insights on Bretisilocin From AJ Cannon, MD

“Engineered Addiction”: Redefining Addictive Disorders and the Psychiatric Impact of Social Media

Monoamines: A Full House

Paying Attention to the Psychopharmacology Pipeline

ALTO-203, an H3 Inverse Agonist, in Depression: Biomarker and Pharmacodynamic Findings